Publicaciones en colaboración con investigadores/as de University of Messina (12)

2024

  1. Association of early blood-based biomarkers and six-month functional outcomes in conventional severity categories of traumatic brain injury: capturing the continuous spectrum of injury

    eBioMedicine, Vol. 107

2023

  1. Correction to: High arterial oxygen levels and supplemental oxygen administration in traumatic brain injury: insights from CENTER-TBI and OzENTER-TBI (Intensive Care Medicine, (2022), 48, 12, (1709-1725), 10.1007/s00134-022-06884-x)

    Intensive Care Medicine

2022

  1. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study

    Journal of Clinical Medicine, Vol. 11, Núm. 4

  2. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study

    Journal of Clinical Medicine, Vol. 11, Núm. 13

  3. High arterial oxygen levels and supplemental oxygen administration in traumatic brain injury: insights from CENTER-TBI and OzENTER-TBI

    Intensive Care Medicine, Vol. 48, Núm. 12, pp. 1709-1725

  4. Traumatic brain injury: progress and challenges in prevention, clinical care, and research

    The Lancet Neurology, Vol. 21, Núm. 11, pp. 1004-1060

2021

  1. Biomarkers for Traumatic Brain Injury: Data Standards and Statistical Considerations

    Journal of Neurotrauma, Vol. 38, Núm. 18, pp. 2514-2529

  2. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients

    Scientific Reports, Vol. 11, Núm. 1

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Clinical benefit of tamsulosin and the hexanic extract of serenoa repens, in combination or as monotherapy, in patients with moderate/severe luts-bph: A subset analysis of the qualiprost study

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-14

2018

  1. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies

    BJU International, Vol. 122, Núm. 6, pp. 1049-1065

2003

  1. Traumatic acute subdural haematomas of the posterior fossa: Clinicoradiological analysis of 24 patients

    Acta Neurochirurgica, Vol. 145, Núm. 12, pp. 1037-1044